Gemcitabine hydrochloride - 98%, high purity , DNA polymerase (alpha/delta/epsilon) inhibitor, CAS No.122111-03-9, DNA polymerase (alpha/delta/epsilon) inhibitor

  • ≥98%
Item Number
G120180
Grouped product items
SKUSizeAvailabilityPrice Qty
G120180-10mg
10mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$9.90
G120180-50mg
50mg
3
$11.90
G120180-250mg
250mg
3
$13.90
G120180-1g
1g
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$22.90
G120180-5g
5g
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$72.90
G120180-10g
10g
1
$119.90
G120180-25g
25g
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$199.90

Potent, specific deoxycytidine analog

Basic Description

SynonymsEX-A837 | Gemcitabine (as hydrochloride) | Gemcitabine HCL (Gemzar) | INFUGEM | NSC613327 | Gemcitabine hydrochloride [USAN] | LY 188011 hydrochloride | BG164501 | Gemzar (TN) | GEMCITABINE HYDROCHLORIDE [VANDF] | dFdC | dFdCyd | 2′-Deoxy-2′,2′-difluorocy
Specifications & Purity≥98%
Biochemical and Physiological MechanismsGemcitabine hydrochloride is used for treatment of non-small cell lung cancer, pancreatic cancer, mammary cancer, ovarian cancer, bladder cancer, nasopharyngeal carcinoma and non-Hodgkin's lymphoma.Deoxycytidine analog that inhibits DNA synthesis. Metabol
Storage TempStore at 2-8°C
Shipped InWet ice
Action TypeINHIBITOR
Mechanism of actionDNA polymerase (alpha/delta/epsilon) inhibitor
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis.This product is only used for scientific research.

AI Insight

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid504753714
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/504753714
IUPAC Name 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrochloride
INCHI InChI=1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1
InChi Key OKKDEIYWILRZIA-OSZBKLCCSA-N
Canonical SMILES Cl.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F
Isomeric SMILES C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F.Cl
WGK Germany 3
RTECS HA3840000
PubChem CID 60749
Molecular Weight 299.66
Reaxy-Rn 5386970

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

20 results found

Lot NumberCertificate TypeDateItem
F2121157Certificate of AnalysisApr 03, 2025 G120180
E1308012Certificate of AnalysisJan 20, 2025 G120180
K2406359Certificate of AnalysisOct 19, 2024 G120180
K2406358Certificate of AnalysisOct 19, 2024 G120180
K2406357Certificate of AnalysisOct 19, 2024 G120180
K2406356Certificate of AnalysisOct 19, 2024 G120180
D2415054Certificate of AnalysisMar 30, 2024 G120180
D2415058Certificate of AnalysisMar 30, 2024 G120180
D2415057Certificate of AnalysisMar 30, 2024 G120180
D2415056Certificate of AnalysisMar 30, 2024 G120180
D2415055Certificate of AnalysisMar 30, 2024 G120180
D2415053Certificate of AnalysisMar 30, 2024 G120180
J1811195Certificate of AnalysisAug 11, 2022 G120180
J1811194Certificate of AnalysisAug 11, 2022 G120180
F2222019Certificate of AnalysisJun 01, 2022 G120180
F2222056Certificate of AnalysisJun 01, 2022 G120180
F2222060Certificate of AnalysisJun 01, 2022 G120180
F2222062Certificate of AnalysisJun 01, 2022 G120180
F2222064Certificate of AnalysisJun 01, 2022 G120180
I2406189Certificate of AnalysisMay 07, 2021 G120180

Show more⌵

Safety and Hazards(GHS)

Pictogram(s) GHS08
Signal Danger
Hazard Statements

H360:May damage fertility or the unborn child

Precautionary Statements

P201:Obtain special instructions before use.

P308+P313:IF exposed or concerned: Get medical advice/attention.

WGK Germany 3
RTECS HA3840000
Reaxy-Rn 5386970
Merck Index 4386

Related Documents

Reviews

Customer Reviews

Citations of This Product

1. Zhimei Wang, Yuehuan Zhang, Qing Chen, Xin Xiao, Carl Redshaw.  (2023)  Preparation of pelargonic acid vesicles and sustained drug release.  Canadian Journal of Chemistry,  101  (2):   [PMID:] [10.1139/cjc-2022-0075]
2. Yadong Tang,Boxin Huang,Yuqin Dong,Wenlong Wang,Xi Zheng,Wei Zhou,Kun Zhang,Zhiyun Du.  (2017-06-07)  Three-dimensional prostate tumor model based on a hyaluronic acid-alginate hydrogel for evaluation of anti-cancer drug efficacy..  Journal of biomaterials science. Polymer edition,  28  ((14)): (1603-1616).  [PMID:28583017]

References

1. Zhimei Wang, Yuehuan Zhang, Qing Chen, Xin Xiao, Carl Redshaw.  (2023)  Preparation of pelargonic acid vesicles and sustained drug release.  Canadian Journal of Chemistry,  101  (2):   [PMID:] [10.1139/cjc-2022-0075]
2. Yadong Tang,Boxin Huang,Yuqin Dong,Wenlong Wang,Xi Zheng,Wei Zhou,Kun Zhang,Zhiyun Du.  (2017-06-07)  Three-dimensional prostate tumor model based on a hyaluronic acid-alginate hydrogel for evaluation of anti-cancer drug efficacy..  Journal of biomaterials science. Polymer edition,  28  ((14)): (1603-1616).  [PMID:28583017]

Solution Calculators